!!Massimo Pinzani - Curriculum Vitae
\\
__Education__
\\
*1979 Medical School Diploma (MD), University of Florence, Italy\\
*1988 PhD Diploma in Clinical and Experimental Hepatology\\
\\
__Postgraduate Training__
\\
*1979 - 1980 Internship in Gastroenterology, Department of Medicine, University of Florence School of Medicine, Florence, Italy\\
*1979 - 1985 Postgraduate School in Internal Medicine, University of Florence School of Medicine, Florence, Italy\\
*1981 - 1982 Military service: First Lieutenant Paratrooper Brigade "Folgore", Pisa, Italy. Italian, USA Military parachuting licence. Specific training: a. Airborne Emergency Medicine; b. prevention of drug abuse and blood-borne infections \\
*1985 Italian National Board Qualification in Internal Medicine\\
*1984 - 1986 Clinical and Research Fellow, Division of Gastroenterology, Harbor-UCLA. Medical Center, Torrance, California, U.S.A. 
*1988 - 1990 Post-Doctoral Fellow, Department of Medicine, Case Western Reserve University, Cleveland, Ohio, U.S.A.
\\
__Academic/Foreign Institutions__
\\
*2009 - present Visiting Professor Division of Hepatology, Osaka City University School of Medicine, Osaka, Japan\\
*2009 - present Adjunct Professor of Gastroenterology and Hepatology, Department of Medicine, Division of Gastroenterology and Hepatology, Case Western Reserve University, Cleveland, Ohio, USA\\
*2019 - 2021 Guest Professor and Scientific Advisor, Norwegian Center for PSC-research, university of Oslo, Oslo, Norway \\
*2020 - 2022 Mayo Clinic, Rochester, MN, USA. Extramural Advisory Committee (EAC) for Primary Sclerosing Cholangitis (PSC) \\
*2020 - 2023 Institutional member, international PhD program in Clinical Sciences, University of Florence, Florence, Italy\\
*2022 - present Member of the Scientific Advisory Board, IRCSS San Matteo, University of Pavia, Italy
\\
__Scientific Societies/Foundations/Public Healthcare/Consortia__
\\
*Associazione Italiana per lo Studio del Fegato (AISF), 1990-present.\\
*American Association for the Study of Liver Diseases (AASLD), 1988-present.\\
*European Association for the Study of the Liver (EASL) 1986-present (Member of Advisory Board 2003-2006); Member of the Governing Board as Educational Commissioner and Chair for Education 2015-2019.\\
*United European Gastroenterology (UEG) (Member of the Scientific Committee 2004-2009)\\
*Fondazione Italiana per lo Studio del Fegato, Italian Liver Foundation (Board of Directors Member, 1999-2012)\\
*International Ascites Club (Member of the Scientific Committee Member, 1998 - 2001)\\
*European Club for Liver Cell Biology (Founder), 2000 - present \\
*International Study Group for Stem Cell Therapy, 2007 - 2010 \\
*International Society for Hepatic Sinusoid Research (ISHSR), President-elect 2010, President 2011 \\
*Phoenix Stem Cell Foundation for Human Life (Member of the Scientific Committee, 2009 - 2011)\\
*Fondazione Italiana per la Ricerca Epatologica (FIRE) (Italian Foundation for Liver Research) (Board of Directors Member, 2010 - 2013)\\
*London Cancer UCLP, HBP cancer pathway, Board Member (Research), 2012 - present \\
*Association of Physicians of Great Britain and Ireland (2013-present)\\
*EASL Consortium for Regenerative Hepatology, Founder and Chairman (2018 - 2022)\\
*Institutional/Council  Boards UK: Medical Research Council (MRC) Population and System Medicine Board Member  (2014 - 2018)\\
\\
__Patents__\\
\\
1. EP 00109063.8 Assessment of liver fibrosis scoring with serum marker algorithms (Bayer Pharma AG). \\
\\
2. 014147/ASI/fp Spironolactone derivatives for the inhibition of the pro-fibrogenic action of hepatic stellate cells and of vascular smooth muscle cells. \\
\\
3. RM2007A000088 Colchicine derivatives, pharmaceutical preparation and use as anti-fibrotic and anti-cancer agents. \\
\\
4. UK Patent Application 1409858.6 (2014). Human liver scaffolds.  Inventors: Mazza G, Malago M, De Coppi P, Pinzani M\\
\\
5. UK Patent Application 1513461.2 (2015). Methods and device for the production of decellularised tissue scaffolds. Methods claims: Mazza G, Al-Akkad W, Pinzani M. Device claims: Mazza G, Proctor T, Al-Akkad W, Lowdell M, Pinzani M.\\
\\
6. USA Patent Application n. US2020/0033329 A1 Cantilever sensors for molecule detection. J.W.Ndieyira, S.Patil. G. Mazza, M.Pinzani\\
\\
__Enterprise__
\\
*Engitix Therapeutics Ltd (UK 10290441) - 5 New Street Square, London EC4A 3TW, United Kingdom– Co-Founder and Chair of Scientific Advisory Board\\
*Aculive Therapeutics Ltd (UK 13603426) - 61 Bridge Street Kington Herefordshire HR5 3DJ, United Kingdom – Chief Medical Advisor\\
\\
__Personal Statement__\\
\\
Since the beginning of the 90’s I have established a very competitive research laboratory integrated in the clinical environment of a Liver Unit. This setting allowed the development of several research strategies merging the actual competence of physicians with those of basic scientists operating in the laboratory. The discoveries resulting from these activities are known worldwide and the laboratory has achieved an important international reputation. Large parts of my capabilities in management and leadership are reflected in the success of the laboratory and of some of its active members. The general philosophy of this group of investigators, developed over several years of experience, fully matches the characteristics of what is defined as “translational” medical research, i.e., ability to mediate the passage from basic knowledge to clinical applications, and vice versa. It is worthy to note that this type of physician-scientist is still a rare entity or, alternatively, it is becoming an endangered species in an era where “translational” scientists are highly needed. In agreement with this “translational” philosophy, most of the studies performed have been directed at confirming the evidence obtained in cellular models in animal models of disease and in the actual human disease. \\
\\
My current research interests include: cell and molecular mechanism of hepatic and intestinal fibrogenesis (Crohn’s disease), the role of the hepatic stroma in the development of hepatocellular carcinoma, cholangiocarcinoma and metastatic liver cancer, development of biomarkers and technologies for the non-invasive evaluation of disease progression in Hepatology, design and implementation of anticancer strategies for solid tumours of the GI tract, regenerative Hepatology (preparation of bio-scaffold by flow decellularization and repopulation with inducible pluripotent stem cells), tissue biology and biophysics of cirrhotic liver. \\
\\
__Publications and Citation Report (February 2022)__\\
\\
PubMed: 295 original peer-reviewed publications in international journals\\
H INDEX: 102 SCOPUS \\
Total No. of citations 36137\\ \\[{ALLOW view All}][{ALLOW edit mpinzani}][{ALLOW upload mpinzani}][{ALLOW comment All}]